お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙:眼科用医薬品の市場動向・市場シェア・市場規模の予測 (2021-2028年):疾患 (ドライアイ・アレルギー・緑内障・感染症)・薬剤クラス・剤形・投与経路・製品タイプ・地域別
市場調査レポート
商品コード
989699

眼科用医薬品の市場動向・市場シェア・市場規模の予測 (2021-2028年):疾患 (ドライアイ・アレルギー・緑内障・感染症)・薬剤クラス・剤形・投与経路・製品タイプ・地域別

Ophthalmic Drugs Market Size, Share & Trends Analysis Report By Disease (Dry Eye, Eye Allergy, Glaucoma, Eye Infection), By Drug Class, By Dosage Form, By Route Of Administration, By Product Type, By Region, And Segment Forecasts, 2021 - 2028

出版日: | 発行: Grand View Research, Inc. | ページ情報: 英文 307 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=111.11円
眼科用医薬品の市場動向・市場シェア・市場規模の予測 (2021-2028年):疾患 (ドライアイ・アレルギー・緑内障・感染症)・薬剤クラス・剤形・投与経路・製品タイプ・地域別
出版日: 2021年02月05日
発行: Grand View Research, Inc.
ページ情報: 英文 307 Pages
納期: 2-3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の眼科用医薬品の市場規模は予測期間中6.4%のCAGRで推移し、2028年には603億米ドルの規模に成長すると予測されています。老眼、黄斑変性症、糖尿病性網膜症などの眼性疾患の罹患率の上昇などの要因が同市場の成長を推進しています。

当レポートでは、世界の眼科用医薬品の市場を調査し、市場の定義と概要、市場成長への各種影響因子の分析、関連法規制、製品パイプライン、市場規模の推移・予測、医薬品クラス・疾患・投与経路・剤形・製品タイプ・地域/主要国など各種区分別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

第1章 調査手法・調査範囲

第2章 エグゼクティブサマリー

第3章 市場可変因子・動向・展望

  • 市場の見通し
  • 疫学
  • 規制の枠組み
  • 特許満了動向
  • パイプライン分析
  • コスト構造の分析
  • 市場力学
  • 普及・成長の見通しマッピング
  • 市場分析ツール

第4章 市場予測・動向分析:医薬品クラス別

  • ダッシュボード
  • 市場シェア実績・予測
  • 市場規模の推移・予測
  • 抗アレルギー剤
  • 抗VEGF剤
  • 抗炎症薬
  • 緑内障治療薬
  • その他

第5章 市場予測・動向分析:疾患別

  • ダッシュボード
  • 市場シェア実績・予測
  • 市場規模の推移・予測
  • ドライアイ
  • アレルギー
  • 緑内障
  • 眼感染症
  • 網膜障害
  • ブドウ膜炎
  • その他

第6章 市場予測・動向分析:投与経路別

  • ダッシュボード
  • 市場シェア実績・予測
  • 市場規模の推移・予測
  • 局所剤
  • 点眼剤
  • 全身薬

第7章 市場予測・動向分析:剤形別

  • ダッシュボード
  • 市場シェア実績・予測
  • 市場規模の推移・予測
  • ジェル
  • 眼科用液剤
  • カプセル・錠剤
  • 目薬
  • 軟膏

第8章 市場予測・動向分析:製品タイプ別

  • ダッシュボード
  • 市場シェア実績・予測
  • 市場規模の推移・予測
  • OTC薬
  • 処方薬

第9章 市場予測・動向分析:地域・主要国別

  • ダッシュボード
  • 市場シェア・主要企業
  • 市場シェア実績・予測
  • 市場規模の推移・予測
  • SWOT分析
  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • 中東・アフリカ

第10章 競合分析

  • 主要企業・近年の展開・影響分析
  • 企業の分類
  • ベンダー情勢
  • 公開企業
  • 非公開企業
  • 企業プロファイル
    • ALCON
    • NOVARTIS AG
    • JOHNSON & JOHNSON SERVICES, INC.
    • BAUSCH HEALTH
    • MERCK SHARP & DOHME CORP.
    • REGENERON PHARMACEUTICALS, INC.
    • COHERUS BIOSCIENCES, INC.
    • ALLERGAN
    • PFIZER, INC.
    • BAYER AG
    • SANTEN PHARMACEUTICALS CO. LTD.
    • GENETECH, INC.
図表

List of Tables

  • TABLE 1 List of Abbreviation
  • TABLE 2 North America Ophthalmic Drugs Market, by Country, 2017 - 2028 (USD Million)
  • TABLE 3 North America Ophthalmic Drugs Market, by Drug Class, 2017 - 2028 (USD Million)
  • TABLE 4 North America Anti-inflammatory Market, by Type, 2017 - 2028 (USD Million)
  • TABLE 5 North America Ophthalmic Drugs Market, by Disease, 2017 - 2028 (USD Million)
  • TABLE 6 North America Dry Eye Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 7 North America Eye Allergy Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 8 North America Glaucoma Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 9 North America Infection Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 10 North America Retinal Disorders Market, by Type, 2017 - 2028 (USD Million)
  • TABLE 11 North America Retinal Disorders Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 12 North America Uveitis Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 13 North America Ophthalmic Drugs Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 14 North America Ophthalmic Drugs Market, by Route of Administration, 2017 - 2028 (USD Million)
  • TABLE 15 North America Ophthalmic Drugs Market, by Product Type, 2017 - 2028 (USD Million)
  • TABLE 16 North America Local Ocular Market, by Type, 2017 - 2028 (USD Million)
  • TABLE 16 U.S. Ophthalmic Drugs Market, by Drug Class, 2017 - 2028 (USD Million)
  • TABLE 17 U.S. Anti-inflammatory Market, by Type, 2017 - 2028 (USD Million)
  • TABLE 18 U.S. Ophthalmic Drugs Market, by Disease, 2017 - 2028 (USD Million)
  • TABLE 19 U.S. Dry Eye Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 20 U.S. Eye Allergy Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 21 U.S. Glaucoma Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 22 U.S. Infection Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 23 U.S. Retinal Disorders Market, by Type, 2017 - 2028 (USD Million)
  • TABLE 24 U.S. Retinal Disorders Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 25 U.S. Uveitis Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 26 U.S. Ophthalmic Drugs Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 27 U.S. Ophthalmic Drugs Market, by Route of Administration, 2017 - 2028 (USD Million)
  • TABLE 28 U.S. Ophthalmic Drugs Market, by Product Type, 2017 - 2028 (USD Million)
  • TABLE 29 U.S. Local Ocular Market, by Type, 2017 - 2028 (USD Million)
  • TABLE 30 Canada Ophthalmic Drugs Market, by Drug Class, 2017 - 2028 (USD Million)
  • TABLE 31 Canada Anti-inflammatory Market, by Type, 2017 - 2028 (USD Million)
  • TABLE 32 Canada Ophthalmic Drugs Market, by Disease, 2017 - 2028 (USD Million)
  • TABLE 33 Canada Dry Eye Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 34 Canada Eye Allergy Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 35 Canada Glaucoma Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 36 Canada Infection Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 37 Canada Retinal Disorders Market, by Type, 2017 - 2028 (USD Million)
  • TABLE 38 Canada Retinal Disorders Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 39 Canada Uveitis Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 40 Canada Ophthalmic Drugs Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 41 Canada Ophthalmic Drugs Market, by Route of Administration, 2017 - 2028 (USD Million)
  • TABLE 42 Canada Ophthalmic Drugs Market, by Product Type, 2017 - 2028 (USD Million)
  • TABLE 43 Canada Local Ocular Market, by Type, 2017 - 2028 (USD Million)
  • TABLE 44 Europe Ophthalmic Drugs Market, by Country, 2017 - 2028 (USD Million)
  • TABLE 44 Europe Ophthalmic Drugs Market, by Drug Class, 2017 - 2028 (USD Million)
  • TABLE 45 Europe Anti-inflammatory Market, by Type, 2017 - 2028 (USD Million)
  • TABLE 46 Europe Ophthalmic Drugs Market, by Disease, 2017 - 2028 (USD Million)
  • TABLE 47 Europe Dry Eye Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 48 Europe Eye Allergy Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 49 Europe Glaucoma Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 50 Europe Infection Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 51 Europe Retinal Disorders Market, by Type, 2017 - 2028 (USD Million)
  • TABLE 52 Europe Retinal Disorders Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 53 Europe Uveitis Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 54 Europe Ophthalmic Drugs Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 55 Europe Ophthalmic Drugs Market, by Route of Administration, 2017 - 2028 (USD Million)
  • TABLE 56 Europe Ophthalmic Drugs Market, by Product Type, 2017 - 2028 (USD Million)
  • TABLE 57 Europe Local Ocular Market, by Type, 2017 - 2028 (USD Million)
  • TABLE 58 U.K. Ophthalmic Drugs Market, by Drug Class, 2017 - 2028 (USD Million)
  • TABLE 59 U.K. Anti-inflammatory Market, by Type, 2017 - 2028 (USD Million)
  • TABLE 60 U.K. Ophthalmic Drugs Market, by Disease, 2017 - 2028 (USD Million)
  • TABLE 61 U.K. Dry Eye Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 62 U.K. Eye Allergy Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 63 U.K. Glaucoma Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 64 U.K. Infection Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 65 U.K. Retinal Disorders Market, by Type, 2017 - 2028 (USD Million)
  • TABLE 66 U.K. Retinal Disorders Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 67 U.K. Uveitis Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 68 U.K. Ophthalmic Drugs Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 69 U.K. Ophthalmic Drugs Market, by Route of Administration, 2017 - 2028 (USD Million)
  • TABLE 70 U.K. Ophthalmic Drugs Market, by Product Type, 2017 - 2028 (USD Million)
  • TABLE 71 U.K. Local Ocular Market, by Type, 2017 - 2028 (USD Million)
  • TABLE 72 Germany Ophthalmic Drugs Market, by Drug Class, 2017 - 2028 (USD Million)
  • TABLE 73 Germany Anti-inflammatory Market, by Type, 2017 - 2028 (USD Million)
  • TABLE 74 Germany Ophthalmic Drugs Market, by Disease, 2017 - 2028 (USD Million)
  • TABLE 75 Germany Dry Eye Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 76 Germany Eye Allergy Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 77 Germany Glaucoma Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 78 Germany Infection Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 79 Germany Retinal Disorders Market, by Type, 2017 - 2028 (USD Million)
  • TABLE 80 Germany Retinal Disorders Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 81 Germany Uveitis Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 82 Germany Ophthalmic Drugs Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 83 Germany Ophthalmic Drugs Market, by Route of Administration, 2017 - 2028 (USD Million)
  • TABLE 84 Germany Ophthalmic Drugs Market, by Product Type, 2017 - 2028 (USD Million)
  • TABLE 85 Germany Local Ocular Market, by Type, 2017 - 2028 (USD Million)
  • TABLE 86 France Ophthalmic Drugs Market, by Drug Class, 2017 - 2028 (USD Million)
  • TABLE 87 France Anti-inflammatory Market, by Type, 2017 - 2028 (USD Million)
  • TABLE 88 France Ophthalmic Drugs Market, by Disease, 2017 - 2028 (USD Million)
  • TABLE 89 France Dry Eye Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 90 France Eye Allergy Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 91 France Glaucoma Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 92 France Infection Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 93 France Retinal Disorders Market, by Type, 2017 - 2028 (USD Million)
  • TABLE 94 France Retinal Disorders Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 95 France Uveitis Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 96 France Ophthalmic Drugs Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 97 France Ophthalmic Drugs Market, by Route of Administration, 2017 - 2028 (USD Million)
  • TABLE 98 France Ophthalmic Drugs Market, by Product Type, 2017 - 2028 (USD Million)
  • TABLE 99 France Local Ocular Market, by Type, 2017 - 2028 (USD Million)
  • TABLE 100 Italy Ophthalmic Drugs Market, by Drug Class, 2017 - 2028 (USD Million)
  • TABLE 101 Italy Anti-inflammatory Market, by Type, 2017 - 2028 (USD Million)
  • TABLE 102 Italy Ophthalmic Drugs Market, by Disease, 2017 - 2028 (USD Million)
  • TABLE 103 Italy Dry Eye Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 104 Italy Eye Allergy Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 105 Italy Glaucoma Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 106 Italy Infection Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 107 Italy Retinal Disorders Market, by Type, 2017 - 2028 (USD Million)
  • TABLE 108 Italy Retinal Disorders Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 109 Italy Uveitis Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 110 Italy Ophthalmic Drugs Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 111 Italy Ophthalmic Drugs Market, by Route of Administration, 2017 - 2028 (USD Million)
  • TABLE 112 Italy Ophthalmic Drugs Market, by Product Type, 2017 - 2028 (USD Million)
  • TABLE 113 Italy Local Ocular Market, by Type, 2017 - 2028 (USD Million)
  • TABLE 114 Spain Ophthalmic Drugs Market, by Drug Class, 2017 - 2028 (USD Million)
  • TABLE 115 Spain Anti-inflammatory Market, by Type, 2017 - 2028 (USD Million)
  • TABLE 116 Spain Ophthalmic Drugs Market, by Disease, 2017 - 2028 (USD Million)
  • TABLE 117 Spain Dry Eye Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 118 Spain Eye Allergy Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 119 Spain Glaucoma Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 120 Spain Infection Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 121 Spain Retinal Disorders Market, by Type, 2017 - 2028 (USD Million)
  • TABLE 122 Spain Retinal Disorders Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 123 Spain Uveitis Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 124 Spain Ophthalmic Drugs Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 125 Spain Ophthalmic Drugs Market, by Route of Administration, 2017 - 2028 (USD Million)
  • TABLE 126 Spain Ophthalmic Drugs Market, by Product Type, 2017 - 2028 (USD Million)
  • TABLE 127 Spain Local Ocular Market, by Type, 2017 - 2028 (USD Million)
  • TABLE 128 Russia Ophthalmic Drugs Market, by Drug Class, 2017 - 2028 (USD Million)
  • TABLE 129 Russia Anti-inflammatory Market, by Type, 2017 - 2028 (USD Million)
  • TABLE 130 Russia Ophthalmic Drugs Market, by Disease, 2017 - 2028 (USD Million)
  • TABLE 131 Russia Dry Eye Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 132 Russia Eye Allergy Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 133 Russia Glaucoma Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 134 Russia Infection Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 135 Russia Retinal Disorders Market, by Type, 2017 - 2028 (USD Million)
  • TABLE 136 Russia Retinal Disorders Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 137 Russia Uveitis Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 138 Russia Ophthalmic Drugs Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 139 Russia Ophthalmic Drugs Market, by Route of Administration, 2017 - 2028 (USD Million)
  • TABLE 140 Russia Ophthalmic Drugs Market, by Product Type, 2017 - 2028 (USD Million)
  • TABLE 141 Russia Local Ocular Market, by Type, 2017 - 2028 (USD Million)
  • TABLE 142 Asia Pacific Ophthalmic Drugs Market, by Country, 2017 - 2028 (USD Million)
  • TABLE 142 Asia Pacific Ophthalmic Drugs Market, by Drug Class, 2017 - 2028 (USD Million)
  • TABLE 143 Asia Pacific Anti-inflammatory Market, by Type, 2017 - 2028 (USD Million)
  • TABLE 144 Asia Pacific Ophthalmic Drugs Market, by Disease, 2017 - 2028 (USD Million)
  • TABLE 145 Asia Pacific Dry Eye Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 146 Asia Pacific Eye Allergy Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 147 Asia Pacific Glaucoma Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 148 Asia Pacific Infection Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 149 Asia Pacific Retinal Disorders Market, by Type, 2017 - 2028 (USD Million)
  • TABLE 150 Asia Pacific Retinal Disorders Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 151 Asia Pacific Uveitis Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 152 Asia Pacific Ophthalmic Drugs Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 153 Asia Pacific Ophthalmic Drugs Market, by Route of Administration, 2017 - 2028 (USD Million)
  • TABLE 154 Asia Pacific Ophthalmic Drugs Market, by Product Type, 2017 - 2028 (USD Million)
  • TABLE 155 Asia Pacific Local Ocular Market, by Type, 2017 - 2028 (USD Million)
  • TABLE 156 Japan Ophthalmic Drugs Market, by Drug Class, 2017 - 2028 (USD Million)
  • TABLE 157 Japan Anti-inflammatory Market, by Type, 2017 - 2028 (USD Million)
  • TABLE 158 Japan Ophthalmic Drugs Market, by Disease, 2017 - 2028 (USD Million)
  • TABLE 159 Japan Dry Eye Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 160 Japan Eye Allergy Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 161 Japan Glaucoma Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 162 Japan Infection Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 163 Japan Retinal Disorders Market, by Type, 2017 - 2028 (USD Million)
  • TABLE 164 Japan Retinal Disorders Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 165 Japan Uveitis Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 166 Japan Ophthalmic Drugs Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 167 Japan Ophthalmic Drugs Market, by Route of Administration, 2017 - 2028 (USD Million)
  • TABLE 168 Japan Ophthalmic Drugs Market, by Product Type, 2017 - 2028 (USD Million)
  • TABLE 169 Japan Local Ocular Market, by Type, 2017 - 2028 (USD Million)
  • TABLE 170 China Ophthalmic Drugs Market, by Drug Class, 2017 - 2028 (USD Million)
  • TABLE 171 China Anti-inflammatory Market, by Type, 2017 - 2028 (USD Million)
  • TABLE 172 China Ophthalmic Drugs Market, by Disease, 2017 - 2028 (USD Million)
  • TABLE 173 China Dry Eye Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 174 China Eye Allergy Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 175 China Glaucoma Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 176 China Infection Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 177 China Retinal Disorders Market, by Type, 2017 - 2028 (USD Million)
  • TABLE 178 China Retinal Disorders Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 179 China Uveitis Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 180 China Ophthalmic Drugs Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 181 China Ophthalmic Drugs Market, by Route of Administration, 2017 - 2028 (USD Million)
  • TABLE 182 China Ophthalmic Drugs Market, by Product Type, 2017 - 2028 (USD Million)
  • TABLE 183 China Local Ocular Market, by Type, 2017 - 2028 (USD Million)
  • TABLE 184 India Ophthalmic Drugs Market, by Drug Class, 2017 - 2028 (USD Million)
  • TABLE 185 India Anti-inflammatory Market, by Type, 2017 - 2028 (USD Million)
  • TABLE 186 India Ophthalmic Drugs Market, by Disease, 2017 - 2028 (USD Million)
  • TABLE 187 India Dry Eye Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 188 India Eye Allergy Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 189 India Glaucoma Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 190 India Infection Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 191 India Retinal Disorders Market, by Type, 2017 - 2028 (USD Million)
  • TABLE 192 India Retinal Disorders Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 193 India Uveitis Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 194 India Ophthalmic Drugs Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 195 India Ophthalmic Drugs Market, by Route of Administration, 2017 - 2028 (USD Million)
  • TABLE 196 India Ophthalmic Drugs Market, by Product Type, 2017 - 2028 (USD Million)
  • TABLE 197 India Local Ocular Market, by Type, 2017 - 2028 (USD Million)
  • TABLE 198 South Korea Ophthalmic Drugs Market, by Drug Class, 2017 - 2028 (USD Million)
  • TABLE 199 South Korea Anti-inflammatory Market, by Type, 2017 - 2028 (USD Million)
  • TABLE 200 South Korea Ophthalmic Drugs Market, by Disease, 2017 - 2028 (USD Million)
  • TABLE 201 South Korea Dry Eye Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 202 South Korea Eye Allergy Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 203 South Korea Glaucoma Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 204 South Korea Infection Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 205 South Korea Retinal Disorders Market, by Type, 2017 - 2028 (USD Million)
  • TABLE 206 South Korea Retinal Disorders Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 207 South Korea Uveitis Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 208 South Korea Ophthalmic Drugs Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 209 South Korea Ophthalmic Drugs Market, by Route of Administration, 2017 - 2028 (USD Million)
  • TABLE 210 South Korea Ophthalmic Drugs Market, by Product Type, 2017 - 2028 (USD Million)
  • TABLE 211 South Korea Local Ocular Market, by Type, 2017 - 2028 (USD Million)
  • TABLE 212 Australia Ophthalmic Drugs Market, by Drug Class, 2017 - 2028 (USD Million)
  • TABLE 213 Australia Anti-inflammatory Market, by Type, 2017 - 2028 (USD Million)
  • TABLE 214 Australia Ophthalmic Drugs Market, by Disease, 2017 - 2028 (USD Million)
  • TABLE 215 Australia Dry Eye Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 216 Australia Eye Allergy Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 217 Australia Glaucoma Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 218 Australia Infection Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 219 Australia Retinal Disorders Market, by Type, 2017 - 2028 (USD Million)
  • TABLE 220 Australia Retinal Disorders Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 221 Australia Uveitis Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 222 Australia Ophthalmic Drugs Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 223 Australia Ophthalmic Drugs Market, by Route of Administration, 2017 - 2028 (USD Million)
  • TABLE 224 Australia Ophthalmic Drugs Market, by Product Type, 2017 - 2028 (USD Million)
  • TABLE 225 Australia Local Ocular Market, by Type, 2017 - 2028 (USD Million)
  • TABLE 226 Singapore Ophthalmic Drugs Market, by Drug Class, 2017 - 2028 (USD Million)
  • TABLE 227 Singapore Anti-inflammatory Market, by Type, 2017 - 2028 (USD Million)
  • TABLE 228 Singapore Ophthalmic Drugs Market, by Disease, 2017 - 2028 (USD Million)
  • TABLE 229 Singapore Dry Eye Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 230 Singapore Eye Allergy Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 231 Singapore Glaucoma Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 232 Singapore Infection Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 233 Singapore Retinal Disorders Market, by Type, 2017 - 2028 (USD Million)
  • TABLE 234 Singapore Retinal Disorders Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 235 Singapore Uveitis Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 236 Singapore Ophthalmic Drugs Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 237 Singapore Ophthalmic Drugs Market, by Route of Administration, 2017 - 2028 (USD Million)
  • TABLE 238 Singapore Ophthalmic Drugs Market, by Product Type, 2017 - 2028 (USD Million)
  • TABLE 239 Singapore Local Ocular Market, by Type, 2017 - 2028 (USD Million)
  • TABLE 240 Latin America Ophthalmic Drugs Market, by Country, 2017 - 2028 (USD Million)
  • TABLE 240 Latin America Ophthalmic Drugs Market, by Drug Class, 2017 - 2028 (USD Million)
  • TABLE 241 Latin America Anti-inflammatory Market, by Type, 2017 - 2028 (USD Million)
  • TABLE 242 Latin America Ophthalmic Drugs Market, by Disease, 2017 - 2028 (USD Million)
  • TABLE 243 Latin America Dry Eye Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 244 Latin America Eye Allergy Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 245 Latin America Glaucoma Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 246 Latin America Infection Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 247 Latin America Retinal Disorders Market, by Type, 2017 - 2028 (USD Million)
  • TABLE 248 Latin America Retinal Disorders Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 249 Latin America Uveitis Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 250 Latin America Ophthalmic Drugs Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 251 Latin America Ophthalmic Drugs Market, by Route of Administration, 2017 - 2028 (USD Million)
  • TABLE 252 Latin America Ophthalmic Drugs Market, by Product Type, 2017 - 2028 (USD Million)
  • TABLE 253 Latin America Local Ocular Market, by Type, 2017 - 2028 (USD Million)
  • TABLE 254 Brazil Ophthalmic Drugs Market, by Drug Class, 2017 - 2028 (USD Million)
  • TABLE 255 Brazil Anti-inflammatory Market, by Type, 2017 - 2028 (USD Million)
  • TABLE 256 Brazil Ophthalmic Drugs Market, by Disease, 2017 - 2028 (USD Million)
  • TABLE 257 Brazil Dry Eye Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 258 Brazil Eye Allergy Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 259 Brazil Glaucoma Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 260 Brazil Infection Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 261 Brazil Retinal Disorders Market, by Type, 2017 - 2028 (USD Million)
  • TABLE 262 Brazil Retinal Disorders Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 263 Brazil Uveitis Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 264 Brazil Ophthalmic Drugs Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 265 Brazil Ophthalmic Drugs Market, by Route of Administration, 2017 - 2028 (USD Million)
  • TABLE 266 Brazil Ophthalmic Drugs Market, by Product Type, 2017 - 2028 (USD Million)
  • TABLE 267 Brazil Local Ocular Market, by Type, 2017 - 2028 (USD Million)
  • TABLE 268 Mexico Ophthalmic Drugs Market, by Drug Class, 2017 - 2028 (USD Million)
  • TABLE 269 Mexico Anti-inflammatory Market, by Type, 2017 - 2028 (USD Million)
  • TABLE 270 Mexico Ophthalmic Drugs Market, by Disease, 2017 - 2028 (USD Million)
  • TABLE 271 Mexico Dry Eye Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 272 Mexico Eye Allergy Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 273 Mexico Glaucoma Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 274 Mexico Infection Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 275 Mexico Retinal Disorders Market, by Type, 2017 - 2028 (USD Million)
  • TABLE 276 Mexico Retinal Disorders Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 277 Mexico Uveitis Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 278 Mexico Ophthalmic Drugs Market, by Dosage Form, 2017 - 2028 (USD Million)
  • TABLE 279 Mexico Ophthalmic Drugs Market, by Route of Administration, 2017 - 2028 (USD Million)
  • TABLE 280 Mexico Ophthalmic Drugs Market, by Product Type, 2017 - 2028 (USD Million)
  • TABLE 281 Mexico Local Ocular Market, by Type, 2017 - 2028 (USD Million)

List of Figures

  • FIG. 1 Market research process
  • FIG. 2 Information procurement
  • FIG. 3 Market summary
  • FIG. 4 Market segmentation & scope
  • FIG. 5 Market size and growth prospects
  • FIG. 6 Global ophthalmic drugs- Key market driver analysis
  • FIG. 7 Global ophthalmic drugs market - Key market restraint analysis
  • FIG. 8 Penetration & growth prospect mapping
  • FIG. 9 Factors estimated to impact on market growth
  • FIG. 10 Global ophthalmic drugs market - Porter's analysis
  • FIG. 11 Global ophthalmic drugs market - PESTEL analysis
  • FIG. 12 Global ophthalmic drugs market drug class outlook key takeaways
  • FIG. 13 Global ophthalmic drugs market: Drug Class movement analysis
  • FIG. 14 Antiallergy market estimates, 2017 - 2028 (USD Million)
  • FIG. 15 Anti-VEGF agents market estimates, 2017 - 2028 (USD Million)
  • FIG. 16 Anti-inflammatory market estimates, 2017 - 2028 (USD Million)
  • FIG. 17 Non-steroidal drugs market estimates, 2017 - 2028 (USD Million)
  • FIG. 18 Steroidal market estimates, 2017 - 2028 (USD Million)
  • FIG. 19 Antiglaucoma market estimates, 2017 - 2028 (USD Million)
  • FIG. 20 Others market estimates, 2017 - 2028 (USD Million)
  • FIG. 21 Global ophthalmic drugs market disease outlook key takeaways
  • FIG. 22 Global ophthalmic drugs market: Disease movement analysis
  • FIG. 23 Dry eye market estimates, 2017 - 2028 (USD Million)
  • FIG. 24 Eye Allergy market estimates, 2017 - 2028 (USD Million)
  • FIG. 25 Glaucoma market estimates, 2017 - 2028 (USD Million)
  • FIG. 26 Eye Infection market estimates, 2017 - 2028 (USD Million)
  • FIG. 27 Retinal disorders market estimates, 2017 - 2028 (USD Million)
  • FIG. 28 Macular degeneration market estimates, 2017 - 2028 (USD Million)
  • FIG. 29 Diabetic retinopathy market estimates, 2017 - 2028 (USD Million)
  • FIG. 30 Others market estimates, 2017 - 2028 (USD Million)
  • FIG. 31 Uveitis market estimates, 2017 - 2028 (USD Million)
  • FIG. 32 Others market estimates, 2017 - 2028 (USD Million)
  • FIG. 33 Global ophthalmic drugs market dosage form outlook key takeaways
  • FIG. 34 Global ophthalmic drugs market: Dosage Form movement analysis
  • FIG. 35 Gels market estimates, 2017 - 2028 (USD Million)
  • FIG. 36 Eye solutions market estimates, 2017 - 2028 (USD Million)
  • FIG. 37 Capsules & tablets market estimates, 2017 - 2028 (USD Million)
  • FIG. 38 Eye drops market estimates, 2017 - 2028 (USD Million)
  • FIG. 39 Ointments market estimates, 2017 - 2028 (USD Million)
  • FIG. 40 Global ophthalmic drugs market route of administration outlook key takeaways
  • FIG. 41 Global ophthalmic drugs market: Route of administration movement analysis
  • FIG. 42 Topical market estimates, 2017 - 2028 (USD Million)
  • FIG. 43 Local ocular market estimates, 2017 - 2028 (USD Million)
  • FIG. 44 Subconjunctival market estimates, 2017 - 2028 (USD Million)
  • FIG. 45 Intravitreal market estimates, 2017 - 2028 (USD Million)
  • FIG. 46 Retrobulbar market estimates, 2017 - 2028 (USD Million)
  • FIG. 47 Intracameral market estimates, 2017 - 2028 (USD Million)
  • FIG. 48 Systemic market estimates, 2017 - 2028 (USD Million)
  • FIG. 49 Global ophthalmic drugs market product type outlook key takeaways
  • FIG. 50 Global ophthalmic drugs market: Product type movement analysis
  • FIG. 51 Prescription drugs market estimates, 2017 - 2028 (USD Million)
  • FIG. 52 OTC drugs market estimates, 2017 - 2028 (USD Million)
  • FIG. 53 Regional market place: Key takeaways
  • FIG. 54 Global ophthalmic drugs market: Regional movement analysis
  • FIG. 55 North America ophthalmic drugs market, 2017 - 2028 (USD Million)
  • FIG. 56 U.S. ophthalmic drugs market, 2017 - 2028 (USD Million)
  • FIG. 57 Canada ophthalmic drugs market, 2017 - 2028 (USD Million)
  • FIG. 58 Europe ophthalmic drugs market, 2017 - 2028 (USD Million)
  • FIG. 59 U.K. ophthalmic drugs market, 2017 - 2028 (USD Million)
  • FIG. 60 Germany ophthalmic drugs market, 2017 - 2028 (USD Million)
  • FIG. 61 France ophthalmic drugs market, 2017 - 2028 (USD Million)
  • FIG. 62 Spain ophthalmic drugs market, 2017 - 2028 (USD Million)
  • FIG. 63 Italy ophthalmic drugs market, 2017 - 2028 (USD Million)
  • FIG. 64 Russia ophthalmic drugs market, 2017 - 2028 (USD Million)
  • FIG. 65 Asia Pacific ophthalmic drugs market, 2017 - 2028 (USD Million)
  • FIG. 66 Japan ophthalmic drugs market, 2017 - 2028 (USD Million)
  • FIG. 67 China ophthalmic drugs market, 2017 - 2028 (USD Million)
  • FIG. 68 India ophthalmic drugs market, 2017 - 2028 (USD Million)
  • FIG. 69 South Korea ophthalmic drugs market, 2017 - 2028 (USD Million)
  • FIG. 70 Singapore ophthalmic drugs market, 2017 - 2028 (USD Million)
  • FIG. 71 Australia ophthalmic drugs market, 2017 - 2028 (USD Million)
  • FIG. 72 Latin America ophthalmic drugs market, 2017 - 2028 (USD Million)
  • FIG. 73 Brazil ophthalmic drugs market, 2017 - 2028 (USD Million)
  • FIG. 74 Mexico ophthalmic drugs market, 2017 - 2028 (USD Million)
  • FIG. 75 Argentina ophthalmic drugs market, 2017 - 2028 (USD Million)
  • FIG. 76 Middle East & Africa ophthalmic drugs market, 2017 - 2028 (USD Million)
  • FIG. 77 South Africa ophthalmic drugs market, 2017 - 2028 (USD Million)
  • FIG. 78 UAE ophthalmic drugs market, 2017 - 2028 (USD Million)
  • FIG. 79 Saudi Arabia ophthalmic drugs market, 2017 - 2028 (USD Million)
  • FIG. 80 Strategy framework
目次
Product Code: GVR-2-68038-010-1

Ophthalmic Drug Market Growth & Trends

The global ophthalmic drugs market size is expected to reach USD 60.3 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 6.4% from 2021 to 2028. An increase in the prevalence of eye-related disorders, such as presbyopia, macular degeneration, and diabetic retinopathy, is one of the major drivers of the market. According to the American Academy of Ophthalmology, over 2.71 million people in the U.S. were affected by Primary Open-angle Glaucoma (POAG) in 2011, and the number is estimated to reach 7.3 million by 2050.

Moreover, due to COVID-19, it has become increasingly unsafe for individuals to touch their face several times a day, which is a known cause of transmission. Therefore, companies are developing long-acting, hands-free therapies to combat such challenges. For instance, in April 2020, Ocular Therapeutix, Inc. completed Phase III clinical trial to evaluate the safety and efficacy of DEXTENZA for allergic conjunctivitis. It is a hands-free therapy administered in the office setting as an intracanalicular insert. It is bioresorbable and designed to release the corticosteroid dexamethasone to the ocular surface, lasting 30 days. It is a one-time and long-acting therapy that can be useful during the COVID-19 crisis.

Investors are increasingly funding companies to support the clinical development of novel treatments for eye diseases thereby fueling the market growth. For instance, in February 2019, Oyster Point Pharma, Inc. received USD 93 million series B financing from Invus Opportunities, Flying L Partners, New Enterprise Associates (NEA), Versant Ventures, and Vida Ventures. The company's product candidates include OC-01 and OC-02 in a Phase 2b clinical trial.

In addition, increasing development and approval of new laboratory methods is expected to boost the market growth. For instance, in July 2020, Quest Diagnostics received emergency Use Authorization (EUA) from the U.S. FDA for a laboratory technique that was developed for extracting viral RNA. This new technique was designed to expand the testing capacity of COVID-19 molecular tests.

Furthermore, key players in the market undertake various strategies to strengthen their product portfolios and offer diverse, technologically advanced, and innovative products. For instance, in September 2019, Alcon introduced iLUX Patient Care Kits to support practices in treating people with dry eyes in the U.S.

Ophthalmic Drug Market Report Highlights

  • In 2020, anti-VEGF agents dominated the market owing to high preference by ophthalmologists, enhanced tissue penetration, and rapid responsive rates
  • Retinal disorders was the fastest-growing disease segment in 2020 owing to an increase in the prevalence of age-related macular degeneration and diabetic retinopathy, technological advancements, and rising strategic collaborations
  • The topical route of administration dominated the market in 2020 due to the high patient compliance, non-invasiveness, and self-administrability
  • The eye drops segment is estimated to witness the fastest growth over the forecast period due to impending launches of several ophthalmic solutions and suspensions in the near future and its direct drug delivery mechanism
  • North America dominated the market and accounted for the largest revenue share in 2020 owing to the rising consumer awareness, high disease burden, technological advancements, and proactive government measures

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market Segmentation and Scope
    • 1.1.1 Segment Scope
    • 1.1.2 Regional Scope
    • 1.1.3 Estimates And Forecast Timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased Database
    • 1.3.2 Gvr's Internal Database
    • 1.3.3 Secondary Sources
    • 1.3.4 Primary Research
    • 1.3.5 Details Of Primary Research
  • 1.4 Information Or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis
      • 1.6.1.1 Approach 1: Commodity Flow Approach
      • 1.6.1.2 Approach 2: Country Wise Market Estimation Using Bottom Up Approach
      • 1.6.1.3 Approach 3: Country Wise Market Estimation Using Top Down Approach
  • 1.7 List Of Secondary Sources
  • 1.8 List Of Abbreviations
  • 1.9 Objectives
    • 1.9.1 Objective 1
    • 1.9.2 Objective 2
    • 1.9.3 Objective 3
    • 1.9.4 Objective 4

Chapter 2 Executive Summary

  • 2.1 Market Outlook
  • 2.2 Segment Outlook
  • 2.3 Competitive Insights

Chapter 3 Ophthalmic Drugs Market Variables, Trends, & Scope

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent Market
  • 3.2 Epidemiology
    • 3.2.1 Dry Eyes
    • 3.2.2 Glaucoma
    • 3.2.3 Retinal Disorders
    • 3.2.4 Uveitis
    • 3.2.5 Eye Infection/ Inflammation
    • 3.2.6 Eye Allergy
  • 3.3 Regulatory Framework
    • 3.3.1 Regulatory Bodies, By Region
    • 3.3.2 North America
    • 3.3.3 Europe
    • 3.3.4 Asia Pacific
    • 3.3.5 Latin America
    • 3.3.6 Middle East & Africa
  • 3.4 Patent Expiry Analysis
  • 3.5 Pipeline Analysis
    • 3.5.1 Pipeline Analysis, By Phase (Funder Type- Industry)
    • 3.5.2 Pipeline Analysis, By Phase (Funder Type- All Others)
  • 3.6 Cost Structure Analysis
  • 3.7 Market Dynamics
    • 3.7.1 Market Drivers Analysis
      • 3.7.1.1 Increasing Disease Prevalence
      • 3.7.1.2 Strong Developmental Pipeline
      • 3.7.1.3 Advancements In Drug Delivery
      • 3.7.1.4 Promising Investment Scenario
    • 3.7.2 Market Restraint Analysis
      • 3.7.2.1 Patent Expiry Of Blockbuster Drugs
  • 3.8 Penetration & Growth Prospect Mapping
  • 3.9 Ophthalmic Drugs: Market Analysis Tools
    • 3.9.1 Industry Analysis - Porter's
    • 3.9.2 Pestle Analysis
    • 3.9.3 Major Deals And Strategic Alliances
      • 3.9.3.1 New Product Launch
      • 3.9.3.2 Acquisition
      • 3.9.3.3 Expansion
      • 3.9.3.4 Partnerships
      • 3.9.3.5 Marketing & Promotions
  • 3.10 Primary Research Analysis
    • 3.10.1 Market Scenario
    • 3.10.2 Key Kol Responses

Chapter 4 Ophthalmic Drugs Market: Segment Analysis, By Drug Class, 2017 - 2028 (USD Million)

  • 4.1 Definition And Scope
  • 4.2 Drug Class Market Share Analysis, 2020 & 2028
  • 4.3 Segment Dashboard
  • 4.4 Global Ophthalmic Drugs Market, By Drug Class, 2017 - 2028 (USD Million)
  • 4.5 Market Size & Forecasts And Trend Analyses, 2017 - 2028 (USD Million)
    • 4.5.1 Antiallergy
      • 4.5.1.1 Antiallergy Market, 2017 - 2028 (USD Million)
    • 4.5.2 Anti-Vegf Agents
      • 4.5.2.1 Anti-Vegf Agents Market, 2017 - 2028 (USD Million)
    • 4.5.3 Anti-Inflammatory
      • 4.5.3.1 Anti-Inflammatory Market, 2017 - 2028 (USD Million)
      • 4.5.3.2 Non-Steroidal Anti-Inflammatory Drugs
      • 4.5.3.2.1 Non-Steroidal Anti-Inflammatory Market, 2017 - 2028 (USD Million)
      • 4.5.3.3 Steroidal Anti-Inflammatory Drugs
      • 4.5.3.3.1 Steroidal Anti-Inflammatory Market, 2017 - 2028 (USD Million)
    • 4.5.4 Antiglaucoma
      • 4.5.4.1 Antiglaucoma Market, 2017 - 2028 (USD Million)
    • 4.5.5 Others
      • 4.5.5.1 Others Market, 2017 - 2028 (USD Million)

Chapter 5 Ophthalmic Drugs Market: Segment Analysis, By Disease, 2017 - 2028 (USD Million)

  • 5.1 Definition And Scope
  • 5.2 Disease Market Share Analysis, 2020 & 2028
  • 5.3 Segment Dashboard
  • 5.4 Global Ophthalmic Drugs Market, By Disease, 2017 - 2028 (USD Million)
  • 5.5 Market Size & Forecasts And Trend Analyses, 2017 - 2028 (USD Million)
    • 5.5.1 Dry Eye
      • 5.5.1.1 Dry Eye Market, 2017 - 2028 (USD Million)
    • 5.5.2 Eye Allergies
      • 5.5.2.1 Eye Allergies Market, 2017 - 2028 (USD Million)
    • 5.5.3 Glaucoma
      • 5.5.3.1 Glaucoma Market, 2017 - 2028 (USD Million)
    • 5.5.4 Eye Infection
      • 5.5.4.1 Eye Infection Market, 2017 - 2028 (USD Million)
    • 5.5.5 Retinal Disorders
      • 5.5.5.1 Retinal Disorders Market, 2017 - 2028 (USD Million)
      • 5.5.5.2 Macular Degeneration
      • 5.5.5.2.1 Macular Degeneration Market, 2017 - 2028 (USD Million)
      • 5.5.5.3 Diabetic Retinopathy
      • 5.5.5.3.1 Diabetic Retinopathy Market, 2017 - 2028 (USD Million)
      • 5.5.5.4 Others
      • 5.5.5.4.1 Others Market, 2017 - 2028 (USD Million)
    • 5.5.6 Uveitis
      • 5.5.6.1 Uveitis Market, 2017 - 2028 (USD Million)
    • 5.5.7 Others
      • 5.5.7.1 Others Market, 2017 - 2028 (USD Million)

Chapter 6 Ophthalmic Drugs Market: Segment Analysis, By Route of Administration, 2017 - 2028 (USD Million)

  • 6.1 Definition and Scope
  • 6.2 Route of Administration Market Share Analysis, 2020 & 2028
  • 6.3 Segment Dashboard
  • 6.4 Global Ophthalmic Drugs Market, by Route of Administration, 2017 - 2028 (USD Million)
  • 6.5 Market Size & Forecasts And Trend Analyses, 2017 - 2028 (USD Million)
    • 6.5.1 TOPICAL
      • 6.5.1.1 Topical Market, 2017 - 2028 (USD Million)
    • 6.5.2 LOCAL OCULAR
      • 6.5.2.1 Local Ocular Market, 2017 - 2028 (USD Million)
      • 6.5.2.2 Subconjunctival
      • 6.5.2.2.1 Subconjunctival Market, 2017 - 2028 (USD Million)
      • 6.5.2.3 Intravitreal
      • 6.5.2.3.1 Intravitreal Market, 2017 - 2028 (USD Million)
      • 6.5.2.4 Retrobulbar
      • 6.5.2.4.1 Retrobulbar Market, 2017 - 2028 (USD Million)
      • 6.5.2.5 Intracameral
      • 6.5.2.5.1 Intracameral Market, 2017 - 2028 (USD Million)
    • 6.5.3 SYSTEMIC
      • 6.5.3.1 Systemic Market, 2017 - 2028 (USD Million)

Chapter 7 Ophthalmic Drugs Market: Segment Analysis, By Dosage Form, 2017 - 2028 (USD Million)

  • 7.1 Definition and Scope
  • 7.2 Dosage Form Market Share Analysis, 2020 & 2028
  • 7.3 Segment Dashboard
  • 7.4 Global Ophthalmic Drugs Market, by Dosage Form, 2017 - 2028 (USD Million)
  • 7.5 Market Size & Forecasts and Trend Analyses, 2017 - 2028 (USD Million)
    • 7.5.1 GELS
      • 7.5.1.1 Gels market, 2017 - 2028 (USD Million)
    • 7.5.2 EYE SOLUTIONS
      • 7.5.2.1 Eye solutions market, 2017 - 2028 (USD Million)
    • 7.5.3 CAPSULES & TABLETS
      • 7.5.3.1 Capsules & tablets market, 2017 - 2028 (USD Million)
    • 7.5.4 EYE DROPS
      • 7.5.4.1 Eye drops market, 2017 - 2028 (USD Million)
    • 7.5.5 OINTMENTS
      • 7.5.5.1 Ointments market, 2017 - 2028 (USD Million)

Chapter 8 Ophthalmic Drugs Market: Segment Analysis, By Product Type, 2017 - 2028 (USD Million)

  • 8.1 Definition and Scope
  • 8.2 Product Type Market Share Analysis, 2020 & 2028
  • 8.3 Segment Dashboard
  • 8.4 Global Ophthalmic Drugs Market, by Product Type, 2017 - 2028 (USD Million)
  • 8.5 Market Size & Forecasts and Trend Analyses, 2017 - 2028 (USD Million)
    • 8.5.1 OTC DRUGS
      • 8.5.1.1 OTC Drugs Market, 2017 - 2028 (USD Million)
    • 8.5.2 PRESCRIPTION DRUGS
      • 8.5.2.1 Prescription Drugs Market, 2017 - 2028 (USD Million)

Chapter 9 Ophthalmic Drugs Market: Segment Analysis, By Region, 2017 - 2028 (USD Million)

  • 9.1 Definition & Scope
  • 9.2 Regional Market Share Analysis, 2020 & 2028
  • 9.3 Regional Market Dashboard
  • 9.4 Regional Market Snapshot
  • 9.5 Regional Market Share and Leading Players, 2020
    • 9.5.1 North America
    • 9.5.2 Europe
    • 9.5.3 Asia Pacific
    • 9.5.4 Latin America
    • 9.5.5 Middle East & Africa
  • 9.6 Swot Analysis
    • 9.6.1 North America
    • 9.6.2 Europe
    • 9.6.3 Asia Pacific
    • 9.6.4 Latin America
    • 9.6.5 Middle East & Africa
  • 9.7 Market Size, & Forecasts, Revenue and Trend Analysis, 2020 - 2028 (USD Million)
    • 9.7.1 NORTH AMERICA
      • 9.7.1.1 North America Ophthalmic Drugs Market, 2017-2028 (USD Million)
      • 9.7.1.2 U.S.
      • 9.7.1.2.1 U.S. Ophthalmic Drugs Market, 2017 - 2028 (USD Million)
      • 9.7.1.3 Canada
      • 9.7.1.3.1 Canada Ophthalmic Drugs Market, 2017 - 2028 (USD Million)
    • 9.7.2 EUROPE
      • 9.7.2.1 Europe Ophthalmic Drugs Market, 2017 - 2028 (USD Million)
      • 9.7.2.2 U.K.
      • 9.7.2.2.1 U.K. Ophthalmic Drugs Market, 2017 - 2028 (USD Million)
      • 9.7.2.3 Germany
      • 9.7.2.3.1 Germany Ophthalmic Drugs Market, 2017 - 2028 (USD Million)
      • 9.7.2.4 France
      • 9.7.2.4.1 France Ophthalmic Drugs Market, 2017 - 2028 (USD Million)
      • 9.7.2.5 Italy
      • 9.7.2.5.1 Italy Ophthalmic Drugs Market, 2017 - 2028 (USD Million)
      • 9.7.2.6 Spain
      • 9.7.2.6.1 Spain Ophthalmic Drugs Market, 2017 - 2028 (USD Million)
      • 9.7.2.7 Russia
      • 9.7.2.7.1 Russia Ophthalmic Drugs Market, 2017 - 2028 (USD Million)
    • 9.7.3 ASIA PACIFIC
      • 9.7.3.1 Asia Pacific Ophthalmic Drugs Market, 2017 - 2028 (USD Million)
      • 9.7.3.2 Japan
      • 9.7.3.2.1 Japan Ophthalmic Drugs Market, 2017 - 2028 (USD Million)
      • 9.7.3.3 China
      • 9.7.3.3.1 China Ophthalmic Drugs Market, 2017 - 2028 (USD Million)
      • 9.7.3.4 India
      • 9.7.3.4.1 India Ophthalmic Drugs Market, 2017 - 2028 (USD Million)
      • 9.7.3.5 Australia
      • 9.7.3.5.1 Australia Ophthalmic Drugs Market, 2017 - 2028 (USD Million)
      • 9.7.3.6 South Korea
      • 9.7.3.6.1 South Korea Ophthalmic Drugs Market, 2017 - 2028 (USD Million)
      • 9.7.3.7 Singapore
      • 9.7.3.7.1 Singapore Ophthalmic Drugs Market, 2017 - 2028 (USD Million)
    • 9.7.4 LATIN AMERICA
      • 9.7.4.1 Latin America Ophthalmic Drugs Market, 2017 - 2028 (USD Million)
      • 9.7.4.2 Mexico
      • 9.7.4.2.1 Mexico Ophthalmic Drugs Market, 2017 - 2028 (USD Million)
      • 9.7.4.3 Brazil
      • 9.7.4.3.1 Brazil Ophthalmic Drugs Market, 2017 - 2028 (USD Million)
      • 9.7.4.4 Argentina
      • 9.7.4.4.1 Argentina Ophthalmic Drugs Market, 2017 - 2028 (USD Million)
    • 9.7.5 MIDDLE EAST & AFRICA
      • 9.7.5.1 Middle East & Africa Ophthalmic Drugs Market, 2017 - 2028 (USD Million)
      • 9.7.5.2 South Africa
      • 9.7.5.2.1 South Africa Ophthalmic Drugs Market, 2017 - 2028 (USD Million)
      • 9.7.5.3 UAE
      • 9.7.5.3.1 UAE Ophthalmic Drugs Market, 2017 - 2028 (USD Million)
      • 9.7.5.4 Saudi Arabia
      • 9.7.5.4.1 Saudi Arabia Ophthalmic Drugs Market, 2017 - 2028 (USD Million)

CHAPTER 10 Ophthalmic Drugs Market - Competitive Analysis

  • 10.1 Recent Developments & Impact Analysis, by Key Market Participants
    • 10.1.1 ANSOFF MATRIX
    • 10.1.2 HEAT MAP ANALYSIS
  • 10.2 Company Categorization
    • 10.2.1 INNOVATORS
    • 10.2.2 MARKET LEADERS
  • 10.3 Vendor Landscape
    • 10.3.1 LIST OF KEY DISTRIBUTORS AND CHANNEL PARTNERS
    • 10.3.2 KEY CUSTOMERS
    • 10.3.3 KEY COMPANY MARKET SHARE ANALYSIS, 2020
  • 10.4 Public Companies
    • 10.4.1 COMPANY MARKET POSITION ANALYSIS
    • 10.4.2 COMPANY MARKET SHARE, BY REGION
    • 10.4.3 COMPETITIVE DASHBOARD ANALYSIS
      • 10.4.3.1 Market Differentiators
  • 10.5 Private Companies
    • 10.5.1 LIST OF KEY EMERGING COMPANIES
    • 10.5.2 REGIONAL NETWORK MAP
    • 10.5.3 COMPANY MARKET POSITION ANALYSIS
  • 10.6 Company Profiles
    • 10.6.1 ALCON
      • 10.6.1.1 Company Overview
      • 10.6.1.2 Financial Performance
      • 10.6.1.3 Product Benchmarking
      • 10.6.1.4 Geographical Footprint
      • 10.6.1.5 Strategic Initiatives
    • 10.6.2 NOVARTIS AG
      • 10.6.2.1 Company Overview
      • 10.6.2.2 Financial Performance
      • 10.6.2.3 Product Benchmarking
      • 10.6.2.4 Geographic Footprint
      • 10.6.2.5 Strategic Initiatives
    • 10.6.3 JOHNSON & JOHNSON SERVICES, INC.
      • 10.6.3.1 Company Overview
      • 10.6.3.2 Financial Performance
      • 10.6.3.3 Product Benchmarking
      • 10.6.3.4 Geographical Footprint
      • 10.6.3.5 Strategic Initiatives
    • 10.6.4 BAUSCH HEALTH
      • 10.6.4.1 Company Overview
      • 10.6.4.2 Financial Performance
      • 10.6.4.3 Product Benchmarking
      • 10.6.4.4 Geographic Footprint
      • 10.6.4.5 Strategic Initiatives
    • 10.6.5 MERCK SHARP & DOHME CORP.
      • 10.6.5.1 Company Overview
      • 10.6.5.2 Financial Performance
      • 10.6.5.3 Product Benchmarking
      • 10.6.5.4 Geographic Footprint
      • 10.6.5.5 Strategic Initiatives
    • 10.6.6 REGENERON PHARMACEUTICALS, INC.
      • 10.6.6.1 Company Overview
      • 10.6.6.2 Financial Performance
      • 10.6.6.3 Product Benchmarking
      • 10.6.6.4 Geographic Footprint
      • 10.6.6.5 Strategic Initiatives
    • 10.6.7 COHERUS BIOSCIENCES, INC.
      • 10.6.7.1 Company Overview
      • 10.6.7.2 Financial Performance
      • 10.6.7.3 Product Benchmarking
    • 10.6.8 ALLERGAN
      • 10.6.8.1 Company Overview
      • 10.6.8.2 Financial Performance
      • 10.6.8.3 Product Benchmarking
      • 10.6.8.4 Geographic Footprint
      • 10.6.8.5 Strategic Initiatives
    • 10.6.9 PFIZER, INC.
      • 10.6.9.1 Company Overview
      • 10.6.9.2 Financial Performance
      • 10.6.9.3 Product Benchmarking
      • 10.6.9.4 Geographic Footprint
    • 10.6.10 BAYER AG
      • 10.6.10.1 Company Overview
      • 10.6.10.2 Financial Performance
      • 10.6.10.3 Product Benchmarking
      • 10.6.10.4 Geographic Footprint
      • 10.6.10.5 Strategic Initiatives
    • 10.6.11 SANTEN PHARMACEUTICALS CO. LTD.
      • 10.6.11.1 Company Overview
      • 10.6.11.2 Financial Performance
      • 10.6.11.3 Product Benchmarking
      • 10.6.11.4 Geographic Footprint
      • 10.6.11.5 Strategic Initiatives
    • 10.6.12 GENETECH, INC.
      • 10.6.12.1 Company Overview
      • 10.6.12.2 Financial Performance
      • 10.6.12.3 Product Benchmarking
      • 10.6.12.4 Geographic Footprint
      • 10.6.12.5 Strategic Initiatives
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.